Improving Healthspan and Increasing Lifespan
Eos SENOLYTIX™ is an affiliate of SENOTHERAPEUTIX, Inc.
Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, along with many others. Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
Eos SENOLYTIX is a longevity company using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs, focused on our proprietary gerotherapeutic peptides, have the remarkable ability to rejuvenate naturally aged mice via two separate mechanisms, both targeting the Mitochondrial Membrane Potential (MMP, ΔΨm), to dramatically eliminate senescent cells throughout the body in the medium to longer term, and to enhance the efficiency of mitochondrial function in aging cells, in the short term, with no apparent adverse side effects. Our peptides work via a completely novel mechanism of action, targeting the lower and declining ΔΨm found in senescent cells compared to non-senescent cells, and in aging cells in general, that develops as we age and that occurs in all living organisms. By targeting the fundamental processes driving aging and aging-related diseases, we have a unique opportunity to intervene in the aging process in ways that were once thought impossible,
In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine have been spun out into three wholly owned subsidiaries of SENOTHERAPEUTIX, Inc.: (1) Eos SENOLYTIX, a longevity company developing novel gerotherapeutic peptides to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel gerotherapeutic peptides to target cancer via this same novel mechanism as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan. Visit our affiliate Companies to learn more about them!
